# LACOG 0415 (NCT02867020)

> Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels

No report yet. It can be ordered.

- Drugs tested: apalutamide; apalutamide plus abiraterone
- Indication: advanced prostate cancer with non-castrate testosterone levels

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02867020
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Latin American Cooperative Oncology Group
- Conditions: Prostate Cancer
- Interventions: Apalutamide; Abiraterone; ADT; Prednisone
- Enrollment: 128
- Primary outcome: Number of patients that achieves an undetectable PSA level, defined as ≤ 0.2 ng/mL

## Indexed commentary on LACOG 0415 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=lacog-0415-nct02867020